ClinicalTrials.gg
Status unknownNCT00546845XXSUpdated Aug 8, 2011

Balloon Angioplasty Versus Xpert Stent in CLI Patients XXS Study

A Phase 4 interventional study of Balloon angioplasty and Use of self-expanding Expert stent in Cronic Limb Ishemia and Intervention, sponsored by University Hospital Tuebingen. Status unknown at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-08-08.

Sponsored by University Hospital Tuebingen · Phase 4, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Oct 2007), so the status shown — last known as Recruiting — may be out of date.
Phase
Phase 4
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study is an investigator-initiated study. The study will be performed as a prospective, randomized, controlled multi-center trial to evaluate the safety and efficiency of Xpert stents compared to PTA in patients with chronic distal artery occlusions or stenosis undergoing catheter revascularization. Patients will be eligible for randomization if they are over 18 years old, if they undergo percutaneous catheter revascularization of an artery below the knee stenosis/occlusion that is less than 15 centimeters in length. Up to two vessels may be treated in this study. All lesions greater than 50% in the below the knee artery region have to be treated either with PTA or stenting according to the randomization.

02

Conditions studied

  • Cronic Limb Ishemia
  • Intervention
03

In context

Lead sponsor

University Hospital Tuebingen is the lead sponsor of 490 studies on the registry; 108 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Clinical:

1. Age between 18 and 95 years. 2. Subject or subject's legal representative have been informed of the nature of the study, and have signed the patient informed consent form. Patient is willing to take part in the follow-up protocol of the XXS study.

3. Rutherford stage 4 and 5 Anatomical:

  1. Additional lesions inflow lesions might be successfully treated before randomization and treatment of the target lesion. The inflow lesions which were treated before randomization should only be classified TASC A or B. (TASC= Trans Atlantic Intersociety Conference)
  2. Target vessel with documented run-off to the foot distally of the index lesion with patent plantar arteries
  3. Reference vessel diameter of the target lesion should be ≥ 2 and ≤ 5 mm.
  4. Maximum treated length in the target vessel is 15 cm (might also be divided up into multiple segments with up to 3 different lesions being treated).
  5. Maximum of treated vessels per leg below the knee: 2 (all treated vessels should be treated within the randomization to the study group [PTA or stenting]).
  6. Minimum distance target lesion to talus is 5 cm.

Exclusion criteria

Exclusion Criteria:

  • Clinical

    1. Life expectancy due to a non-atheroslerotic disease less than 12 months.
    2. Previous bypass surgery \< 30 days prior to the study procedure.
    3. Known allergies or sensitivities to heparin, contrast media, aspirin, clopidogrel, and nitinol which cannot be treated with antihistamines.
    4. eGFR less than 29 mL/min/1.73m2 (K-DOQI Class 4 and 5) in patients which are not currently treated with dialysis (equivalent to a serum creatinine level of 2.4 mg/dL in a 70 year old male patient)
    5. Subject with breast feeding plans, or child bearing potential with no birth control.
    6. Subjects enrolled in another study concerning the index vessel(s) within 3 months prior to the study procedure.
    7. Untreatable bleeding diatheses.
    8. Patients who have an indication of being treated with coumadin after the intervention.
    9. Inability to ambulate
    10. Hypercoagulable state
    11. Patients with age \<18 years and patients who are not able to sign the informed consent form

Anatomical:

  1. Inflow is obstructed and cannot be successfully treated prior to randomization and treatment of below the knee arteries.
  2. Acute thrombus present in the target limb.
  3. Previously implanted stent in the target vessel(s).
  4. Aneurysms in the index leg.
  5. Index vessel with no documented run-up to the foot (please also see inclusion criteria, anatomical).
  6. Inability to use femoral access
  7. No patent pedal arteries
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
180 participants (estimated)

Interventions

  • DeviceBalloon angioplasty

    Balloon angioplasty. Only stent if PTA fails

  • DeviceUse of self-expanding Expert stent

    Nitinol stent

06

What researchers measure

Primary outcomes

  1. MLD at the target lesion assessed by angiography

    treatment effect dependent if stent of PTA was choosen

    Time frame: after 12 +/-2 months

Secondary outcomes

  1. 1. Interventional success rate. Interventional success is defined as restenosis less than 50%. 2. Late lumen loss (LLL)

    treatment effect dependent on the PTA vs. Stent

    Time frame: after 1, 6, 12 months and 3 years

  2. 3. Binary restenosis

    Treament effect in long-term

    Time frame: arter 6, 12 months and 3 years

  3. 4. Number of patients initially randomized to the PTA group, but receiving stents because of the suboptimal interventional success.

    success rate of PTA only

    Time frame: intervention

  4. Target lesion revascularization, clinical stage, hospital days

    treatment effect dependet if patients received stents or PTA only

    Time frame: after 1, 6, 12 months, and 3 years

07

Study locations

1 of 1 sites recruiting
  • Universtiy of Tuebingen
    Tübingen, Baden-Wurttemberg 72076, Germany
    • Gunnar Tepe, MD · Contact · gunnar.tepe@med.uni-tuebingen.de · 49 7071 2983371
    • Thomas Zeller, MD · Sub investigator
    • Dierk Scheinert, MD · Sub investigator
    • Marc Bosiers, MD · Sub investigator
    • Gerhard Rümenapf, MD · Sub investigator
    • Johannes Lammer, MD · Sub investigator
    • Ernst Pilger, MD · Sub investigator
    • Werner Jaschke, MD · Sub investigator
    • Dammis Vrougindeweij, MD · Sub investigator
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2007, a primary completion of Mar 2012 and a completion of Jun 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 17, 2007
First posted
Oct 19, 2007
Start
Sep 2007
Primary completionEst.
Mar 2012
CompletionEst.
Jun 2014
Last update
Aug 8, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 8, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00546845
First posted
Oct 19, 2007
Start date
Sep 2007
Primary completion
Mar 2012 (estimated)
Completion
Jun 2014 (estimated)
Last update
Aug 8, 2011

Study contacts

Gunnar Tepe, MD
Contact
gunnar.tepe@med.uni-tuebingen.de
49 7071 2983371
Jane Gollub
Contact
jane.gollub@med.uni-tuebingen.de
49 7071 2983371
Gunnar Tepe, MD
principal investigator · University Hospital Tuebingen

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2007. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion